Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Genetics · Glycogen Storage Disease Type Ia

The Future of GSD Ia: Emerging Treatments and Hope

At a Glance

Emerging treatments for Glycogen Storage Disease Type Ia (GSD Ia) are focusing on fixing the underlying genetic cause rather than just managing symptoms. Promising research includes AAV gene therapy to deliver healthy G6PC1 genes, CRISPR base editing, and new liver and kidney medications.

While the daily routine of managing Glycogen Storage Disease Type Ia (GSD Ia) is currently intensive, the landscape of treatment is undergoing a major shift. Research is moving toward therapies that aim to fix the underlying genetic cause rather than just managing the symptoms.

Gene Therapy: Replacing the Missing “Key”

The most advanced area of research involves adeno-associated virus (AAV) gene therapy.

  • How it works: Scientists use a harmless virus (AAV) as a delivery truck to carry a healthy, functional copy of the G6PC1 gene directly into the liver cells [1][2].
  • Current Status: A leading gene therapy candidate (DTX401) has reached Phase 3 clinical trials, the final stage before potential approval. Early results in adults showed that many patients were able to increase their fasting time and significantly reduce their reliance on cornstarch [3][2]. Long-term monitoring programs are now tracking these patients to see if the effects last for a decade or more [T-6HOAK010].

The Next Frontier: Gene and Base Editing

Beyond replacing the gene, researchers are looking at ways to “edit” the DNA itself.

  • CRISPR-Cas9: This technology acts like molecular scissors to cut and repair the mutated gene [4][5].
  • Base Editing: This is an even more precise tool that can change a single “letter” of DNA without cutting the strand [6]. A Phase 1/2 trial (BEAM-301) is currently recruiting adults with the specific R83C mutation to test if this can permanently correct the disease [T-70T9SIAH].

New Pharmacological Targets

While gene therapy works on the “root” cause, other medications are being tested to help the liver and kidneys:

  • Liver Health: Researchers are investigating “liver-specific thyromimetics” and medications like bezafibrate to help the liver process fat better and reduce the risk of tumors [2][7].
  • Kidney Health: To protect the kidneys, scientists are exploring Wnt/beta-catenin inhibitors and SGLT2 inhibitors, which may help prevent the scarring and protein leakage associated with GSD Ia nephropathy [8].

A Note on Liver Transplantation

For some children, a liver transplant remains the only definitive way to “reset” the body’s metabolism [9].

  • The Benefit: A successful transplant provides a new liver with working enzymes, which typically resolves the risk of hypoglycemia and other metabolic issues [9].
  • The Risk: Transplantation is a major surgery that requires lifelong immunosuppressant drugs (to prevent the body from rejecting the new organ) and does not fix the enzyme deficiency in the kidneys [10]. It is usually reserved for children who cannot achieve metabolic stability through diet or those who develop suspicious liver tumors [9].

The progress in GSD Ia research is moving faster than ever before. While dietary therapy is your primary tool today, these emerging treatments offer a future where management might be significantly simpler and more effective [11][1].

Return to the Understanding Your Child’s GSD Ia Diagnosis.

Common questions in this guide

What is gene therapy for GSD Ia and how does it work?
Gene therapy for GSD Ia uses a harmless virus, known as AAV, to deliver a healthy, functional copy of the G6PC1 gene directly into liver cells. This treatment aims to correct the root cause of the disease and significantly reduce the need for constant dietary management like cornstarch.
Can CRISPR or base editing cure GSD Ia?
Researchers are currently testing CRISPR and base editing technologies to permanently correct specific DNA mutations that cause GSD Ia, such as the R83C mutation. While still in early clinical trials, these tools act like precise molecular scissors to repair the gene directly.
When is a liver transplant recommended for GSD Ia?
A liver transplant provides a new liver with working enzymes, which can resolve hypoglycemia and other metabolic issues. However, it is a major surgery requiring lifelong immunosuppressant drugs, so it is usually reserved for children who cannot achieve stability through diet or who develop liver tumors.
Are there new medications to protect the liver and kidneys in GSD Ia?
Yes, researchers are exploring targeted medications to manage organ health alongside dietary therapies. This includes investigating drugs like bezafibrate to help the liver process fat, as well as SGLT2 inhibitors to prevent kidney scarring and protein leakage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is our child's specific mutation, such as R83C, one that might make them a candidate for upcoming gene therapy or base editing trials?
  2. 2.When do you expect the current Phase 3 gene therapy trials (like DTX401) to become available for pediatric patients?
  3. 3.Are there any medications in the research pipeline, like bezafibrate or SGLT2 inhibitors, that could help manage our child's liver or kidney health now?
  4. 4.What are the specific criteria that would make a liver transplant a better option for our child than continuing with dietary management?
  5. 5.How do we sign up for registries or monitoring programs to stay informed about new clinical trials as our child gets older?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Liver-Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia.

    Lee C, Pratap K, Zhang L, et al.

    Journal of inherited metabolic disease 2025; (48(4)):e70048 doi:10.1002/jimd.70048.

    PMID: 40443300
  2. 2

    Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.

    Waskowicz LR, Zhou J, Landau DJ, et al.

    Human molecular genetics 2019; (28(1)):143-154 doi:10.1093/hmg/ddy343.

    PMID: 30256948
  3. 3

    Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia.

    Kang HR, Waskowicz L, Seifts AM, et al.

    Molecular therapy. Methods & clinical development 2019; (13()):265-273 doi:10.1016/j.omtm.2019.02.002.

    PMID: 30859111
  4. 4

    CRISPR/Cas9-based double-strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type-Ia.

    Samanta A, George N, Arnaoutova I, et al.

    Journal of inherited metabolic disease 2023; (46(6)):1147-1158 doi:10.1002/jimd.12660.

    PMID: 37467014
  5. 5

    Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.

    Arnaoutova I, Zhang L, Chen HD, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2021; (29(4)):1602-1610 doi:10.1016/j.ymthe.2020.12.027.

    PMID: 33359667
  6. 6

    Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia.

    Arnaoutova I, Aratyn-Schaus Y, Zhang L, et al.

    Nature communications 2024; (15(1)):9729 doi:10.1038/s41467-024-54108-1.

    PMID: 39523369
  7. 7

    A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.

    Zhou J, Waskowicz LR, Lim A, et al.

    Thyroid : official journal of the American Thyroid Association 2019; (29(8)):1158-1167 doi:10.1089/thy.2019.0007.

    PMID: 31337282
  8. 8

    Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia.

    Lee C, Pratap K, Zhang L, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2024; (1870(1)):166874 doi:10.1016/j.bbadis.2023.166874.

    PMID: 37666439
  9. 9

    Liver Transplantation as a Metabolic Treatment in Glycogen Storage Disease Type Ia.

    Atikcan Simsek DT, Avcı Dursun EM, Senay Ozcalik M, et al.

    JCEM case reports 2025; (3(10)):luaf182 doi:10.1210/jcemcr/luaf182.

    PMID: 40837847
  10. 10

    Letter to the Editors: Concerning "Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia" by Lee et al.

    Brooks ED, Kishnani PS, Koeberl DD

    Journal of inherited metabolic disease 2018; (41(6)):913-914 doi:10.1007/s10545-018-0248-2.

    PMID: 30255460
  11. 11

    Impact of glycogen storage disease type I on adult daily life: a survey.

    Garbade SF, Ederer V, Burgard P, et al.

    Orphanet journal of rare diseases 2021; (16(1)):371 doi:10.1186/s13023-021-02006-w.

    PMID: 34479584

This page provides information on experimental and emerging treatments for GSD Ia for educational purposes only. Always consult your child's metabolic specialist or geneticist before considering clinical trials or altering your current treatment plan.

Get notified when new evidence is published on Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.